Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY)
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The study is to provide reliable estimates of the effect of study treatment on hospital
length of stay through to 28 days after randomisation.
The protocol describes an overarching trial design to provide reliable evidence on the
efficacy of candidate therapies for children hospitalised with PIMS-TS receiving standard of
care. It is an adaptive pragmatic platform trial with an open-label randomisation.
For each pairwise comparison with the 'no additional treatment' arm, the primary objective is
to provide reliable estimates of the effect of study treatments on the duration of hospital
stay after randomisation. New trial arms can be added as evidence emerges that other
candidate therapeutics should be evaluated.